Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 2.994
-0.038 (-1.25%)
Jun 5, 2026, 5:36 PM CET
Oryzon Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12.61 | 12.84 | 7.62 | 15.69 | 16.78 | 12.07 | |
Revenue Growth (YoY) | 58.51% | 68.51% | -51.43% | -6.50% | 38.97% | 3.65% |
Cost of Revenue | 0.33 | 0.33 | 0.31 | 0.27 | 0.5 | 0.85 |
Gross Profit | 12.28 | 12.51 | 7.31 | 15.42 | 16.28 | 11.22 |
Selling, General & Admin | 4.7 | 4.45 | 3.67 | 3.99 | 3.81 | 4.17 |
Other Operating Expenses | 14.34 | 14.6 | 8.14 | 16.31 | 18.16 | 14.86 |
Operating Expenses | 21.78 | 19.21 | 11.97 | 20.46 | 22.16 | 19.2 |
Operating Income | -9.5 | -6.71 | -4.66 | -5.04 | -5.87 | -7.98 |
Interest Expense | - | -0 | -0 | -2.09 | -1.2 | -0.52 |
Interest & Investment Income | 1.66 | 0.84 | 0.21 | 0.04 | 0.01 | 0.01 |
Currency Exchange Gain (Loss) | 0.06 | 0.06 | -0.09 | 0.11 | 0.25 | 0.32 |
Other Non Operating Income (Expenses) | 1.75 | -0.77 | -1.22 | 0.23 | -0.21 | 0 |
EBT Excluding Unusual Items | -6.03 | -6.58 | -5.76 | -6.76 | -7.01 | -8.17 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0 |
Asset Writedown | -0 | -0 | - | - | - | - |
Other Unusual Items | 0.01 | 0.01 | 0.08 | 0.02 | 0.01 | 0.01 |
Pretax Income | -6.03 | -6.57 | -5.68 | -6.75 | -7.01 | -8.17 |
Income Tax Expense | -3.45 | -3.51 | -1.97 | -3.04 | -2.48 | -2.84 |
Net Income | -2.58 | -3.06 | -3.7 | -3.71 | -4.52 | -5.33 |
Net Income to Common | -2.58 | -3.06 | -3.7 | -3.71 | -4.52 | -5.33 |
Shares Outstanding (Basic) | 78 | 78 | 65 | 61 | 55 | 53 |
Shares Outstanding (Diluted) | 78 | 78 | 65 | 61 | 55 | 53 |
Shares Change (YoY) | 19.72% | 19.72% | 6.35% | 10.10% | 4.80% | - |
EPS (Basic) | -0.03 | -0.04 | -0.06 | -0.06 | -0.08 | -0.10 |
EPS (Diluted) | -0.03 | -0.04 | -0.06 | -0.06 | -0.08 | -0.10 |
Free Cash Flow | - | -2.84 | -6 | -0.64 | -2.06 | -4.32 |
Free Cash Flow Per Share | - | -0.04 | -0.09 | -0.01 | -0.04 | -0.08 |
Gross Margin | 97.42% | 97.42% | 95.89% | 98.28% | 97.04% | 92.97% |
Operating Margin | -75.34% | -52.25% | -61.18% | -32.16% | -35.02% | -66.07% |
Profit Margin | -20.43% | -23.83% | -48.62% | -23.63% | -26.96% | -44.15% |
Free Cash Flow Margin | - | -22.09% | -78.70% | -4.05% | -12.25% | -35.82% |
EBITDA | -9.36 | -6.57 | -4.53 | -4.9 | -5.72 | -7.82 |
EBITDA Margin | -74.28% | -51.19% | -59.47% | -31.24% | -34.08% | -64.81% |
D&A For EBITDA | 0.13 | 0.14 | 0.13 | 0.14 | 0.16 | 0.15 |
EBIT | -9.5 | -6.71 | -4.66 | -5.04 | -5.87 | -7.98 |
EBIT Margin | -75.34% | -52.25% | -61.18% | -32.16% | -35.02% | -66.07% |